Acasti Pharma Inc. (NASDAQ:ACST) was founded in 2002 and is headquartered in Laval, Canada. It has 7 full-time employees. It is a biopharmaceutical company focusing on the research, development and commercialization of drugs for various cardiometabolic disorders caused by abnormal blood lipids. application.
Acasti Pharma (ACST):
Acasti Pharma Inc. is a biopharmaceutical company specializing in cardiovascular diseases. It is a subsidiary of Neptune Technologies & Bioressources Inc.. Acasti Pharma’s drugs Onemia and CaPre are mainly used to treat and prevent cardiovascular and metabolic diseases.
- Onemia-a medical food (diet therapy), mainly for the dietary management of patients with omega-3 phospholipid deficiency, and related dyslipidemia and cardiometabolic diseases;
- CaPre-the company’s prescription drug candidate product, omega-3 phospholipid therapy, is mainly used for the prevention and treatment of cardiovascular and metabolic disorders, including hypertriglyceridemia. It is currently in phase III clinical trials for the treatment of hypertriglyceridemia.
